Diverse small molecule inhibitors of human apurinic/apyrimidinic endonuclease APE1 identified from a screen of a large public collection

Autor: Anton Simeonov, Daemyung Kim, Vaddadi N. Vyjayanti, David J. Maloney, David M. Wilson, Ajit Jadhav, Dorjbal Dorjsuren
Přispěvatelé: Woloschak, Gayle E
Rok vydání: 2012
Předmět:
DNA Repair
Cancer Treatment
Drug Evaluation
Preclinical

lcsh:Medicine
Biochemistry
Endonuclease
chemistry.chemical_compound
Drug Discovery
Basic Cancer Research
DNA-(Apurinic or Apyrimidinic Site) Lyase
Enzyme Inhibitors
lcsh:Science
Cancer
Multidisciplinary
biology
Molecular Structure
Small molecule
Preclinical
Nucleic acids
Oncology
5.1 Pharmaceuticals
Medicine
Drug
Development of treatments and therapeutic interventions
Research Article
Biotechnology
DNA damage
DNA repair
Cell Survival
General Science & Technology
Dose-Response Relationship
Small Molecule Libraries
Structure-Activity Relationship
DNA-binding proteins
Chemical Biology
Humans
AP site
Biology
Dose-Response Relationship
Drug

lcsh:R
Proteins
DNA
Methyl Methanesulfonate
Molecular biology
Methyl methanesulfonate
chemistry
Small Molecules
Hela Cells
Cancer cell
biology.protein
Drug Evaluation
lcsh:Q
HeLa Cells
DNA Damage
Zdroj: PloS one, vol 7, iss 10
PLoS ONE, Vol 7, Iss 10, p e47974 (2012)
PLoS ONE
Popis: The major human apurinic/apyrimidinic endonuclease APE1 plays a pivotal role in the repair of base damage via participation in the DNA base excision repair (BER) pathway. Increased activity of APE1, often observed in tumor cells, is thought to contribute to resistance to various anticancer drugs, whereas down-regulation of APE1 sensitizes cells to DNA damaging agents. Thus, inhibiting APE1 repair endonuclease function in cancer cells is considered a promising strategy to overcome therapeutic agent resistance. Despite ongoing efforts, inhibitors of APE1 with adequate drug-like properties have yet to be discovered. Using a kinetic fluorescence assay, we conducted a fully-automated high-throughput screen (HTS) of the NIH Molecular Libraries Small Molecule Repository (MLSMR), as well as additional public collections, with each compound tested as a 7-concentration series in a 4 µL reaction volume. Actives identified from the screen were subjected to a panel of confirmatory and counterscreen tests. Several active molecules were identified that inhibited APE1 in two independent assay formats and exhibited potentiation of the genotoxic effect of methyl methanesulfonate with a concomitant increase in AP sites, a hallmark of intracellular APE1 inhibition; a number of these chemotypes could be good starting points for further medicinal chemistry optimization. To our knowledge, this represents the largest-scale HTS to identify inhibitors of APE1, and provides a key first step in the development of novel agents targeting BER for cancer treatment.
Databáze: OpenAIRE